Irbesartan/Hydrochlorothiazide Evolugen Pharma (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochlorothiazide Evolugen Pharma, is an angiotensin II receptor blocker and thiazide diuretic combination presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Irbesartan/Hydrochlorothiazide Evolugen Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce cardiovascular risk. - Essential hypertension: provides sustained blood pressure control when monotherapy is insufficient. - Hypertension with renal impairment: assists in blood pressure management while supporting renal protection.

Irbesartan/Hydrochlorothiazide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination - Mild electrolyte disturbance (e.g., low potassium)

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury - Allergic reactions such as rash or angioedema

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should observe several safety considerations.

- Monitor blood pressure: ensure adequate control without excessive hypotension. - Assess renal function: check serum creatinine and eGFR before initiation and periodically. - Check electrolytes: especially potassium and sodium levels. - Use caution in patients with diabetes: monitor glucose as the diuretic may affect glycaemic control. - Avoid in severe hepatic impairment: limited safety data are available. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant use with potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan concentrations. - Lithium: thiazide component can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hyperkalaemia and renal impairment. - Antidiabetic drugs: thiazide may increase blood glucose, requiring dose adjustment.